Hiroyoshi Taketani

Lower levels of insulin‐like growth factor‐1 standard deviation score are associated with histological severity of non‐alcoholic fatty liver disease

Growth hormone (GH) deficiency may be associated with histological progression of non‐alcoholic fatty liver disease (NAFLD) which includes non‐alcoholic fatty liver (NAFL) and non‐alcoholic steatohepatitis (NASH). Insulin‐like growth factor 1 (IGF‐1) is mainly produced by hepatocytes and its secretion is stimulated by GH. Our aim was to determine whether more histologically advanced NAFLD is associated with low circulating levels of IGF‐1 in Japanese patients.

Predictors of malignancies and overall mortality in Japanese patients with biopsy‐proven non‐alcoholic fatty liver disease

Some patients with non‐alcoholic fatty liver disease (NAFLD) develop hepatocellular carcinoma (HCC) and have higher mortality than others. The evidence causally linking NAFLD to extrahepatic malignancies is scarce. Our aim was to determine the incidence of and risk factors for HCC, extrahepatic cancer and mortality in Japanese patients with biopsy‐proven NAFLD.

Serum alanine aminotransferase predicts the histological course of non‐alcoholic steatohepatitis in Japanese patients

Some cases with non‐alcoholic fatty liver disease (NAFLD), particularly non‐alcoholic steatohepatitis (NASH), can ultimately progress to liver cirrhosis. However, studies to clarify factors predictive of histological change in patients with NASH remain scarce. Our aim is to determine predictors of histological progression in Japanese patients with biopsy‐proven NASH.

Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus.

No pharmacological therapies have been established for non‐alcoholic fatty liver disease (NAFLD). Sodium glucose cotransporter 2 inhibitor (SGLT2I) was developed for the treatment of adults with type 2 diabetes mellitus (T2DM). The aim of this retrospective study is to evaluate the efficacy of SGLT2I in NAFLD patients with T2DM.Aims No pharmacological therapies have been established for nonalcoholic fatty liver disease (NAFLD). Sodium glucose co-transporter 2 inhibitor (SGLT2I) developed for the treatment of adults with type 2 diabetes (T2DM). The aim of this retrospective study is to evaluate the efficacy of SGLT2I in NAFLD patients with T2DM Methods Twenty-four biopsy-proven NAFLD patients with T2DM who received SGLT2I for 24 weeks were retrospectively enrolled as the SGLT2I group. Another 21 NAFLD patients with T2DM treated with dipeptidyl peptidase-4 inhibiter (DPP4I, sitagliptin) for 24 weeks were selected as the DPP4I group. Clinical data were evaluated at baseline and at 4, 12, 24 weeks. Seventeen patients in SGLT2I group were evaluated body composition (Inbody 720) before and after therapy. Results Not only body weight and HbA1c but also transaminase activities were significantly decreased in the SGLT2I group. Reductions in transaminase activities were similar between SGLT2I and DPP4I groups. In the SGLT2I group, body mass index　and fasting plasma glucose also decreased after the treatment. Conclusion SGLT2I can be a novel promising agent for the treatment for NAFLD patients with T2DM. Prospective randomized controlled trial are warranted to confirm this efficacy of SGLT2I on NAFLD with T2DM.

Development of hepatocellular carcinoma in Japanese patients with biopsy-proven non-alcoholic fatty liver disease: Association between PNPLA3 genotype and hepatocarcinogenesis/fibrosis progression

Some patients with non‐alcoholic fatty liver disease (NAFLD) develop hepatocellular carcinoma (HCC). Patatin‐like phospholipase domain containing 3 (PNPLA3) rs738409 (encoding the I148M variant) has been associated with advanced fibrosis and HCC. We determined the risk factors for HCC, including the PNPLA3 rs738409 polymorphism, in Japanese patients with biopsy‐proven NAFLD.

Effect of sodium-glucose cotransporter 2 inhibitor on liver function tests in NAFLD patients with type 2 diabetes in Japan

No pharmacological therapies have been established for non‐alcoholic fatty liver disease (NAFLD). Sodium glucose cotransporter 2 inhibitor (SGLT2I) was developed for the treatment of adults with type 2 diabetes mellitus (T2DM). The aim of this retrospective study is to evaluate the efficacy of SGLT2I in NAFLD patients with T2DM.Aims No pharmacological therapies have been established for nonalcoholic fatty liver disease (NAFLD). Sodium glucose co-transporter 2 inhibitor (SGLT2I) developed for the treatment of adults with type 2 diabetes (T2DM). The aim of this retrospective study is to evaluate the efficacy of SGLT2I in NAFLD patients with T2DM Methods Twenty-four biopsy-proven NAFLD patients with T2DM who received SGLT2I for 24 weeks were retrospectively enrolled as the SGLT2I group. Another 21 NAFLD patients with T2DM treated with dipeptidyl peptidase-4 inhibiter (DPP4I, sitagliptin) for 24 weeks were selected as the DPP4I group. Clinical data were evaluated at baseline and at 4, 12, 24 weeks. Seventeen patients in SGLT2I group were evaluated body composition (Inbody 720) before and after therapy. Results Not only body weight and HbA1c but also transaminase activities were significantly decreased in the SGLT2I group. Reductions in transaminase activities were similar between SGLT2I and DPP4I groups. In the SGLT2I group, body mass index　and fasting plasma glucose also decreased after the treatment. Conclusion SGLT2I can be a novel promising agent for the treatment for NAFLD patients with T2DM. Prospective randomized controlled trial are warranted to confirm this efficacy of SGLT2I on NAFLD with T2DM.

Insulin resistance increases the risk of incident type 2 diabetes mellitus in patients with nonalcoholic fatty liver disease

Type 2 diabetes mellitus (T2DM) is a major complication of patients with non‐alcoholic fatty liver disease (NAFLD). The aim of this retrospective study is to determine the risk factors for development of T2DM in patients with biopsy‐proven NAFLD.

Effect of 12-week dulaglutide therapy in Japanese patients with biopsy-proven non-alcoholic fatty liver disease and type 2 diabetes mellitus.

Aims No pharmacological therapies have been established for nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes mellitus (T2DM). The aim of this retrospective study is to evaluate the efficacy and safety of dulaglutide, a novel glucagon-like peptidase-1 receptor (GLP-1R) agonist in Japanese NAFLD patients with T2DM. Methods Fifteen biopsy-proven NAFLD patients with T2DM refractory to diet intervention who received once weekly dulaglutide 0.75 mg for 12 weeks were retrospectively enrolled after exclusion of two patients dropped off by 12 weeks. In five patients, transient elastography and body composition (Inbody 720) were also evaluated before and after the treatment. Results Not only body weight and HbA1c but also transaminase activities were significantly decreased after the 12wk therapy with dulaglutide. Total body fat mass and liver stiffness measurement also decreased after the treatment. Conclusion Dulaglutide, a new GLP-1R agonist, can be a novel promising agent for the treatment for NAFLD patients with T2DM due to its efficacy of body weight reductions, the nature of weekly injection and patient preference. Prospective randomized controlled trials are warranted to confirm this impact of dulaglutide on NAFLD with T2DM.No pharmacological therapies have been established for non‐alcoholic fatty liver disease (NAFLD) with type 2 diabetes mellitus (T2DM). The aim of this retrospective study is to evaluate the efficacy and safety of dulaglutide, a novel glucagon‐like peptidase‐1 receptor agonist, in Japanese NAFLD patients with T2DM.

Association of coronary artery calcification with liver fibrosis in Japanese patients with NAFLD

Cardiovascular events are the leading cause of death among patients with non‐alcoholic fatty liver disease (NAFLD), but their relationship remains unclear. This study examined the association between coronary atherosclerosis and liver fibrosis, represented by the coronary artery calcification (CAC) score and non‐invasive fibrosis markers, respectively.

Effect of dulaglitide for 12 week in biopsy-proven NAFLD patients with type 2 diabetes in Japan

Aims No pharmacological therapies have been established for nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes mellitus (T2DM). The aim of this retrospective study is to evaluate the efficacy and safety of dulaglutide, a novel glucagon-like peptidase-1 receptor (GLP-1R) agonist in Japanese NAFLD patients with T2DM. Methods Fifteen biopsy-proven NAFLD patients with T2DM refractory to diet intervention who received once weekly dulaglutide 0.75 mg for 12 weeks were retrospectively enrolled after exclusion of two patients dropped off by 12 weeks. In five patients, transient elastography and body composition (Inbody 720) were also evaluated before and after the treatment. Results Not only body weight and HbA1c but also transaminase activities were significantly decreased after the 12wk therapy with dulaglutide. Total body fat mass and liver stiffness measurement also decreased after the treatment. Conclusion Dulaglutide, a new GLP-1R agonist, can be a novel promising agent for the treatment for NAFLD patients with T2DM due to its efficacy of body weight reductions, the nature of weekly injection and patient preference. Prospective randomized controlled trials are warranted to confirm this impact of dulaglutide on NAFLD with T2DM.No pharmacological therapies have been established for non‐alcoholic fatty liver disease (NAFLD) with type 2 diabetes mellitus (T2DM). The aim of this retrospective study is to evaluate the efficacy and safety of dulaglutide, a novel glucagon‐like peptidase‐1 receptor agonist, in Japanese NAFLD patients with T2DM.